Shares of Glenmark Pharmaceuticals will likely remain in demand as the UK Medicines and Healthcare Regulatory Products Agency has allowed the company to sell cromviva capsules, used in the treatment of Gaucher’s disease in the UK. Glenmark’s arm Glenmark Pharmaceuticals Europe Ltd has received the approval for cromviva 100 mg hard capsules on a prescription only basis. In 2013-14 (April—March), Glenmark’s UK business grew 37 per cent year-on-year.

Amtek Auto, Amtek India results on Monday

Shares of Amtek Auto and Amtek India will remain in focus on Monday, as both the companies declare the audited financial results for the year ended September 30. Amtek Auto, the stock of which is entering the derivative segment of the NSE from November 28, posted a net profit of ₹450.72 crore last fiscal and revenue of ₹2,893 crore. For the June quarter, it reported ₹86 crore profit. Amtek India posted a profit of ₹210.29 crore on revenue of ₹2,171.91 crore last fiscal.

Claris Life too gets UK regulator nod

Ahmedabad-based drug maker Claris Lifesciences has received approval from the UK drug regulatory agency to sell milrinone injection and ketorolac trometamol solution for injection in the country. Milrinone injection is used to increase the heart’s contractility in patients who suffer heart failure, while ketorolac trometamol is used as an anti-inflammatory drug. For both the drugs, the UK agency has granted approval on a prescription only basis.

Related Topics